NCT05137847 2023-12-12
A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
Eisai Inc.
Completed
Clinical Trials
22 trialsNCT00003615 2023-06-15
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT01127451 2022-04-13
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Eisai Inc.
Phase 2 Completed
NCT00211185 2020-03-18
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Eisai Inc.
Phase 2 Completed
NCT00357448 2019-05-14
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
University of Washington
Phase 1 Completed
NCT00425672 2018-12-05
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
University of Washington
Phase 1/2 Completed
NCT00880360 2018-03-27
ONTAK
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT00460109 2017-04-18
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00082940 2017-01-19
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
Wake Forest University Health Sciences
Phase 2 Completed
NCT00228358 2014-11-11
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
University of Washington
Phase 1 Completed
NCT00299689 2014-09-05
Phase II Trial of Ontak With Metastatic Melanoma
James Graham Brown Cancer Center
Phase 2 Completed
NCT00082914 2013-06-20
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00006345 2013-05-30
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00138164 2013-05-30
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00278369 2013-05-22
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00128622 2012-11-12
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
Duke University
Phase 1 Completed
NCT00211276 2012-03-14
A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma
Eisai Inc.
Phase 2 Completed
NCT00493129 2012-02-08
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00055146 2009-04-17
Study of ONTAK in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)
Eisai Inc.
Phase 2 Completed
NCT00050999 2008-03-05
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Eisai Inc.
Phase 4 Completed
NCT00051012 2008-03-05
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients
Eisai Inc.
Phase 4 Completed
NCT00211198 2008-03-05
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)
Eisai Inc.
Phase 4 Completed